Combination of ICIs and Cytoreductive Surgery in Metastatic RCC Appears Promising
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
Kidney Cancer
KIDNEY CANCER
Targeted RCC Therapies Benefit ‘Real World’ Medicare Patients
Outside of clinical trials, targeted therapies for advanced renal cell carcinoma in Medicare patients are associated with modest survival advantages over non-targeted therapies.
Benefit Seen from Frontline Pembrolizumab Plus Axitinib in Patients With Intermediate- or Poor-Risk Advanced RCC
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
Combo Shows Promise in Advanced RCC With Brain Metastases
Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.
Checkpoint Inhibitor-Based Combination Prolonged Progression in RCC
No overall survival benefit has yet been seen with the regimen in RCC.
Rise in TSH: A Prognostic Indicator in Sunitinib-Treated Metastatic RCC?
In this study, more than 40% of patients with metastatic RCC showed signs of hypothyroidism following 2 weeks of treatment with sunitinib.
Percutaneous Ablation Appropriate for Localized Renal Tumors
Researchers report long-term follow-up results showing no significant difference in oncologic outcomes among partial nephrectomy, radiofrequency ablation, and cryoablation for cT1 renal tumors.
Bavencio Plus Inlyta Approved as First-Line Tx for Advanced Renal Cell Carcinoma
The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Elevated CRP Before RCC Surgery Predicts Renal Function Decline
Elevated C-reactive protein levels prior to nephrectomy for renal cell carcinoma is associated with an increased risk of renal impairment, a study found.
Left-Sided RCC Linked to Worse Cancer-Specific Survival
In a study, left-sided renal cell carcinoma (RCC) was associated with a 16% to 19% increased risk of dying from the malignancy compared with right-sided RCC.
Want to read more?
Please login or register first to view this content.
Next post in Kidney Cancer
